Anti–immunoglobulin E monoclonal antibody administered with immunotherapy

$39.50 plus tax (Refund Policy)

Buy Article:

Abstract:

Despite both efficacy and immunotolerogenic effects, many clinicians still are reluctant to use allergen-specific immunotherapy (SIT) because of the potential for acute allergic reactions. The anti–immunoglobulin E monoclonal antibody, omalizumab, is approved by the U.S. Food and Drug Administration for the treatment of moderate-to-severe allergic asthma and has proven to be a relatively safe agent. Knowledge of the distinct immunologic changes elicited by allergen SIT and omalizumab has established a rationale for investigation into their combined use for the management of allergic diseases. This review summarizes two investigative studies examining the safety and efficacy of the combination of omalizumab + allergen SIT for the treatment of allergic rhinitis. Both studies show that the combination of omalizumab and allergen SIT confer added efficacy to either treatment alone. Pretreatment of patients with omalizumab before rush allergen immunotherapy also showed added safety to rush immunotherapy with the prevention of acute allergic reactions. Results thus far provide the opportunity to develop strategies using omalizumab pretreatment to enhance the safety and efficacy of allergen-immunotherapy to treat a wide variety of allergic diseases.

Document Type: Research Article

Publication date: March 1, 2006

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more